Latest News

The European Medicines Agency (EMA) has suggested that Welireg (belzutifan) be given a conditional marketing authorization in the EU for people with advanced renal cancer…

European Medicines Agency (EMA) has recommended granting a marketing authorization in the European Union (EU) for Emcitate (tiratricol), an oral medication for individuals with peripheral…

The Holiday season is a busy time for all of us, our friends and our family. Consequently, we could overlook our health in the chaos…

The European Medicines Agency (EMA) has suggested expanding the use of Ofev (nintedanib) to treat progressive fibrosing interstitial lung disorders (ILDs) in children and adolescents…

The updated regulatory framework will expedite trial approvals and promote trial design innovation without affecting patient safety. New laws will be introduced in Parliament to…

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine flortaucipir (Tauvid), a radiopharmaceutical product given to adults with memory problems so that…

Following a review of its initial opinion, EMA suggests revising the recommendations to reduce the possibility of interactions between the weight loss medication Mysimba (naltrexone/bupropion)…

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), a gene therapy based on an adeno-associated virus vector that is recommended for the treatment…

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved new medicine containing active ingredient sparsentan to treat primary immunoglobulin A nephropathy (IgAN). IgA neuropathy,…

After an agency analysis of the available evidence found that oral phenylephrine is ineffective for this use, The U.S. Food and Drug Administration announced is…

The Medicines and Healthcare Products Regulatory Agency (MHRA) is advising medical practitioners to make sure patients are informed about the known adverse effects of agonists…

Sugemalimab, also known as(Equijubi), has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat adult patients with “non-small cell lung cancer.”…

The Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized elafibranor (Iqirvo) for the treatment of adult patients suffering from primary biliary cholangitis (PBC), a…

Hympavzi (marstacimab-hncq) was approved by the U.S. Food and Drug Administration for routine prophylactic use in patients aged 12 and up who have hemophilia A…

An adult COVID-19 vaccine (Comirnaty) that targets the KP.2 subvariant has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA). The immune system’s…